Literature DB >> 27535492

Intraoperative management and early postoperative outcomes of pediatric renal transplants.

Katherine Taylor1,2, Wooheon Thomas Kim1, Malak Maharramova1, Victor Figueroa3, Smruthi Ramesh1, Armando Lorenzo3,4.   

Abstract

INTRODUCTION: Smaller children are presenting for renal transplantation as the treatment of choice for end-stage renal disease. Adult donor organs are more successful than pediatric deceased donor organs. An adult kidney may sequester ~75% of the circulating volume of a 5 year-old child and requires significantly increased cardiac output to maintain renal perfusion. Treatment includes volume, inotropic or vasopressor agents, or central neuroaxial blockade for sympatholysis. We describe the perioperative anesthestic management as a guide to clinical outcomes.
METHODS: A retrospective chart review of renal transplant patients between 2006 and 2014 was performed. We recorded patient demographics, surgical and anesthetic factors and postoperative outcome.
RESULTS: One hundred and fifty-six children underwent renal transplantation, of which 38% were from living donors. There were 99/156 (63.5%) males. Median age was 10 years (range 1-17 years) and the mean weight was 36.2 kg (sd 20.6 kg; range 7.6-109.6 kg). There were 36 children ≤5 years of age and 14 children ≤2 years of age. One hundred and nineteen (77%) were dialysis dependent. Pharmacological support to increase renal perfusion included mannitol in 95%, and dopamine in 83%. Furosemide was used in 82% of cases. Inotropic therapy continued into the postoperative period in 34%. Radiological pulmonary edema was diagnosed in 33% and clinical pulmonary edema in 7%. Intraoperative use of dopamine delayed the time to creatinine nadir in all grafts (9.5 days vs 6.5 days, P = 0.04) and in deceased donor grafts (12.9 vs 7.4 days, P = 0.007). Patients who received dopamine had no significant difference in central venous pressure (CVP) preclamp removal, 14 mmHg vs 11.5 mmHg (P = 0.12) but a higher CVP after clamp removal, 14.3 mmHg vs 11.8 mmHg (P = 0.003).
CONCLUSION: Dopamine use was common and was an independent risk factor for delayed time to creatinine nadir. Many different agents were used to enhance renal perfusion. The 'supra-physiological' hemodynamics resulted in pulmonary edema in 33% of patients.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical outcomes; dopamine; hemodynamic goals; kidney transplantation; pediatrics; retrospective study

Mesh:

Substances:

Year:  2016        PMID: 27535492     DOI: 10.1111/pan.12979

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  4 in total

1.  A Systematic Review and Meta-Analysis Examining the Impact of Sleep Disturbance on Postoperative Delirium.

Authors:  Ayòtúndé B Fadayomi; Reine Ibala; Federico Bilotta; Michael B Westover; Oluwaseun Akeju
Journal:  Crit Care Med       Date:  2018-12       Impact factor: 7.598

Review 2.  Perioperative anesthesia care for the pediatric patient undergoing a kidney transplantation: An educational review.

Authors:  Marieke Voet; Elisabeth A M Cornelissen; Michel F P van der Jagt; Joris Lemson; Ignacio Malagon
Journal:  Paediatr Anaesth       Date:  2021-08-20       Impact factor: 2.129

3.  Extraperitoneal kidney transplantation: a comparison between children weighting ≤15 kg and >15 kg. Experience of a single institution.

Authors:  Filippo Ghidini; Federica De Corti; Francesco Fascetti Leon; Enrico Vidal; Alessandra Rancan; Mattia Parolin; Nicola Zadra; Maurizia Grazzini; Luca Maria Antoniello; Alba Ganarin; Sonia Maita; Costanza Tognon; Guendalina Mognato; Marco Castagnetti; Elisa Benetti; Piergiorgio Gamba; Patrizia Dall'Igna
Journal:  Transpl Int       Date:  2021-09-22       Impact factor: 3.842

4.  Cardiac output-guided hemodynamic therapy for adult living donor kidney transplantation in children under 20 kg: A pilot study.

Authors:  Marieke Voet; Anneliese Nusmeier; Jos Lerou; Josianne Luijten; Marlies Cornelissen; Joris Lemson
Journal:  Paediatr Anaesth       Date:  2019-08-04       Impact factor: 2.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.